%0 Journal Article
%T Impact of targeting transforming growth factor ¦Â-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer
%A Kevin Ng
%A Larn Hwang
%A Osmond J D¡¯Cruz
%A Sanjive Qazi
%A Vuong Trieu
%J Archive of "OncoTargets and therapy".
%D 2018
%R 10.2147/OTT.S161905
%X Overexpression of the cytokine ¨C transforming growth factor-beta 2 (TGF-¦Â2) ¨C has been implicated in the malignant progression of pancreatic cancer (PAC). OT-101 (trabedersen) is an antisense oligodeoxynucleotide designed to target the human TGF-¦Â2 mRNA. In a Phase I/II study, OT-101 treatment with subsequent chemotherapy was characterized by outstanding overall survival (OS) in patients with PAC
%K antisense oligonucleotides
%K biomarkers
%K cytokines
%K pancreatic cancer
%K survival
%K transforming growth factor-beta 2
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5957068/